This is a summary of the European public assessment report (EPAR) for Obizur. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Obizur. For practical information about using Obizur, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Treatment of bleeding episodes in patients with acquired haemophilia caused by antibodies to Factor VIII. Obizur is indicated in adults.
Therapeutic Area (MeSH)
ATC Code
B02
ATC Item
抗出血药
Pharmacotherapeutic Group
Antihemorrhagics
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| susoctocog alfa | N/A | 舒索凝血素α |
EMA Name
Obizur
Medicine Name
Obizur
Aliases
N/ANo risk management plan link.
